• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在门诊环境中实施新冠肺炎的早期治疗:意大利一家三级护理中心面临的挑战及未来展望

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks.

作者信息

Manciulli Tommaso, Lagi Filippo, Barbiero Anna, Fognani Marco, Di Lauria Nicoletta, Malcontenti Costanza, Fiorelli Costanza, Spinicci Michele, Ceccherini Vega, D'Onofrio Paola, Angileri Manuela, Malentacchi Francesca, Cecchi Michele, Rossolini Gian Maria, Tomaiuolo Matteo, Zammarchi Lorenzo, Bartoloni Alessandro

机构信息

Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.

Unit of Infectious and Tropical Diseases, Careggi University Hospital, 50134 Florence, Italy.

出版信息

Infect Dis Rep. 2022 Apr 25;14(3):315-320. doi: 10.3390/idr14030037.

DOI:10.3390/idr14030037
PMID:35645216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9149810/
Abstract

We present a brief commentary illustrating the current COVID-19 outpatient treatment options in Italy. We also report our experience setting up a service dedicated to these patients in the wake of the rise in COVID-19 cases observed in January 2022. We also gathered data on the daily costs faced by our outpatient service, based at a tertiary care center located in Florence, Italy. We present them with some considerations on future outlooks on the use of outpatient treatment in COVID-19.

摘要

我们发表一篇简短评论,阐述意大利目前针对新冠病毒疾病(COVID-19)的门诊治疗方案。我们还报告了在2022年1月观察到COVID-19病例增加后,我们为这些患者设立专门服务的经验。我们还收集了位于意大利佛罗伦萨的一家三级护理中心的门诊服务每日成本数据。我们就COVID-19门诊治疗的未来前景提出了一些思考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0836/9149810/ff4289db8735/idr-14-00037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0836/9149810/ff4289db8735/idr-14-00037-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0836/9149810/ff4289db8735/idr-14-00037-g001.jpg

相似文献

1
Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks.在门诊环境中实施新冠肺炎的早期治疗:意大利一家三级护理中心面临的挑战及未来展望
Infect Dis Rep. 2022 Apr 25;14(3):315-320. doi: 10.3390/idr14030037.
2
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19.抗病毒联合治疗方案作为持续性新冠肺炎免疫功能低下宿主的挽救治疗
J Chemother. 2025 Apr;37(2):130-134. doi: 10.1080/1120009X.2024.2367935. Epub 2024 Jun 14.
3
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort).意大利托斯卡纳地区高危患者的区域队列的真实数据:COVID-19 门诊治疗的安全性和有效性(FEDERATE 队列)。
Viruses. 2023 Feb 5;15(2):438. doi: 10.3390/v15020438.
4
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19.病例报告:索托维单抗、瑞德西韦和奈玛特韦/利托那韦联合用药作为两名因新冠肺炎住院的免疫功能低下患者的挽救治疗方案
Front Med (Lausanne). 2023 Jan 9;9:1062450. doi: 10.3389/fmed.2022.1062450. eCollection 2022.
5
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.莫努匹拉韦和奈玛特韦-利托那韦与轻度至中度COVID-19高危患者的可预防死亡率、住院率及相关可避免的医疗系统成本的关联
Lancet Reg Health West Pac. 2023 Jan;30:100602. doi: 10.1016/j.lanwpc.2022.100602. Epub 2022 Oct 5.
6
Outpatient Management of COVID-19: A Primer for the Dermatologist.新型冠状病毒肺炎的门诊管理:皮肤科医生入门指南。
Curr Dermatol Rep. 2022;11(4):318-327. doi: 10.1007/s13671-022-00368-3. Epub 2022 Aug 20.
7
Table: Treatments considered for COVID-19.表格:针对新型冠状病毒肺炎(COVID-19)考虑的治疗方法。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-e280.
8
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?口服奈玛特韦/利托那韦治疗新冠病毒病:黑暗中的曙光?
Antibiotics (Basel). 2022 Feb 9;11(2):220. doi: 10.3390/antibiotics11020220.
9
Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2.索托维单抗在儿童中的早期应用:一名感染新冠病毒的11岁肾移植受者的病例报告
Children (Basel). 2022 Mar 23;9(4):451. doi: 10.3390/children9040451.
10
Facing SARS-CoV-2 Pandemic at a COVID-19 Regional Children's Hospital in Italy.直面意大利一家 COVID-19 区域儿童医院中的 SARS-CoV-2 大流行。
Pediatr Infect Dis J. 2020 Sep;39(9):e221-e225. doi: 10.1097/INF.0000000000002811.

引用本文的文献

1
Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort).意大利托斯卡纳地区高危患者的区域队列的真实数据:COVID-19 门诊治疗的安全性和有效性(FEDERATE 队列)。
Viruses. 2023 Feb 5;15(2):438. doi: 10.3390/v15020438.
2
[Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment].[脆弱患者的轻度新型冠状病毒2型感染:早期治疗临床路径的实施]
Enferm Infecc Microbiol Clin. 2022 Dec 6. doi: 10.1016/j.eimc.2022.11.004.

本文引用的文献

1
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
2
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
3
Outpatient Therapies for COVID-19: How Do We Choose?新冠病毒病的门诊治疗:我们如何选择?
Open Forum Infect Dis. 2022 Jan 19;9(3):ofac008. doi: 10.1093/ofid/ofac008. eCollection 2022 Mar.
4
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.瑞德西韦早期治疗可降低门诊患者重症 COVID-19 进展风险
N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22.
5
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
6
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused.针对 SARS-CoV-2 的单克隆抗体:仍未充分利用的潜在改变游戏规则者。
Int J Environ Res Public Health. 2021 Oct 24;18(21):11159. doi: 10.3390/ijerph182111159.
7
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
8
Administration of Monoclonal Antibody for COVID-19 in Patient Homes.COVID-19 患者居家环境下使用单克隆抗体治疗。
JAMA Netw Open. 2021 Oct 1;4(10):e2129388. doi: 10.1001/jamanetworkopen.2021.29388.
9
Update to living WHO guideline on drugs for covid-19.世界卫生组织关于新冠肺炎药物的现行指南更新。
BMJ. 2021 Sep 23;374:n2219. doi: 10.1136/bmj.n2219.
10
Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.瑞德西韦和地塞米松治疗住院 COVID-19 患者的成本效用分析——一项假设研究。
BMC Health Serv Res. 2021 Sep 18;21(1):986. doi: 10.1186/s12913-021-06998-w.